Camila Dos Reis Oliveira, Joedna Cavalcante Pereira, Andressa Barros Ibiapina, Italo Rossi Roseno Martins, João Marcelo de Castro E Sousa, Paulo Michel Pinheiro Ferreira, Felipe Cavalcanti Carneiro da Silva
{"title":"Buthionine sulfoximine and chemoresistance in cancer treatments: a systematic review with meta-analysis of preclinical studies.","authors":"Camila Dos Reis Oliveira, Joedna Cavalcante Pereira, Andressa Barros Ibiapina, Italo Rossi Roseno Martins, João Marcelo de Castro E Sousa, Paulo Michel Pinheiro Ferreira, Felipe Cavalcanti Carneiro da Silva","doi":"10.1080/10937404.2023.2246876","DOIUrl":null,"url":null,"abstract":"<p><p>Buthionine sulfoximine (BSO) is a synthetic amino acid that blocks the biosynthesis of reduced glutathione (GSH), an endogenous antioxidant cellular component present in tumor cells. GSH levels have been associated with tumor cell resistance to chemotherapeutic drugs and platinum compounds. Consequently, by depleting GSH, BSO enhances the cytotoxicity of chemotherapeutic agents in drug-resistant tumors. Therefore, the aim of this study was to conduct a systematic review with meta-analysis of preclinical studies utilizing BSO in cancer treatments. The systematic search was carried out using the following databases: PubMed, Web of Science, Scopus, and EMBASE up until March 20, 2023, in order to collect preclinical studies that evaluated BSO, alone or in association, as a strategy for antineoplastic therapy. One hundred nine investigations were found to assess the cytotoxic potential of BSO alone or in combination with other compounds. Twenty-one of these met the criteria for performing the meta-analysis. The evidence gathered indicated that BSO alone exhibits cytotoxic activity. However, this compound is generally used in combination with other antineoplastic strategies, mainly chemotherapy ones, to improve cytotoxicity to carcinogenic cells and treatment efficacy. Finally, this review provides important considerations regarding BSO use in cancer treatment conditions, which might optimize future studies as a potential adjuvant antineoplastic therapeutic tool.</p>","PeriodicalId":49971,"journal":{"name":"Journal of Toxicology and Environmental Health-Part B-Critical Reviews","volume":" ","pages":"417-441"},"PeriodicalIF":6.4000,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Toxicology and Environmental Health-Part B-Critical Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10937404.2023.2246876","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENVIRONMENTAL SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Buthionine sulfoximine (BSO) is a synthetic amino acid that blocks the biosynthesis of reduced glutathione (GSH), an endogenous antioxidant cellular component present in tumor cells. GSH levels have been associated with tumor cell resistance to chemotherapeutic drugs and platinum compounds. Consequently, by depleting GSH, BSO enhances the cytotoxicity of chemotherapeutic agents in drug-resistant tumors. Therefore, the aim of this study was to conduct a systematic review with meta-analysis of preclinical studies utilizing BSO in cancer treatments. The systematic search was carried out using the following databases: PubMed, Web of Science, Scopus, and EMBASE up until March 20, 2023, in order to collect preclinical studies that evaluated BSO, alone or in association, as a strategy for antineoplastic therapy. One hundred nine investigations were found to assess the cytotoxic potential of BSO alone or in combination with other compounds. Twenty-one of these met the criteria for performing the meta-analysis. The evidence gathered indicated that BSO alone exhibits cytotoxic activity. However, this compound is generally used in combination with other antineoplastic strategies, mainly chemotherapy ones, to improve cytotoxicity to carcinogenic cells and treatment efficacy. Finally, this review provides important considerations regarding BSO use in cancer treatment conditions, which might optimize future studies as a potential adjuvant antineoplastic therapeutic tool.
丁硫醚磺酰亚胺（BSO）是一种合成氨基酸，可阻断还原型谷胱甘肽（GSH）的生物合成，GSH是肿瘤细胞中存在的内源性抗氧化细胞成分。GSH水平与肿瘤细胞对化疗药物和铂化合物的耐药性有关。因此，通过消耗GSH，BSO增强了化疗药物在耐药肿瘤中的细胞毒性。因此，本研究的目的是对利用BSO治疗癌症的临床前研究进行系统综述和荟萃分析。截至2023年3月20日，使用以下数据库进行了系统搜索：PubMed、Web of Science、Scopus和EMBASE，以收集评估BSO单独或联合作为抗肿瘤治疗策略的临床前研究。发现109项研究评估了BSO单独或与其他化合物联合的细胞毒性潜力。其中21项符合进行荟萃分析的标准。收集到的证据表明，BSO单独表现出细胞毒性活性。然而，该化合物通常与其他抗肿瘤策略（主要是化疗策略）结合使用，以提高对致癌细胞的细胞毒性和治疗效果。最后，这篇综述提供了关于BSO在癌症治疗条件中的应用的重要考虑，这可能会优化未来作为潜在辅助抗肿瘤治疗工具的研究。
期刊介绍：
"Journal of Toxicology and Environmental Health: Part B - Critical Reviews" is an academic journal published by Taylor & Francis, focusing on the critical examination of research in the areas of environmental exposure and population health. With an ISSN identifier of 1093-7404, this journal has established itself as a significant source of scholarly content in the field of toxicology and environmental health.
Since its inception, the journal has published over 424 articles that have garnered 35,097 citations, reflecting its impact and relevance in the scientific community. Known for its comprehensive reviews, the journal also goes by the names "Critical Reviews" and "Journal of Toxicology & Environmental Health, Part B, Critical Reviews."
The journal's mission is to provide a platform for in-depth analysis and critical discussion of the latest findings in toxicology, environmental health, and related disciplines. By doing so, it contributes to the advancement of knowledge and understanding of the complex interactions between environmental factors and human health, aiding in the development of strategies to protect and improve public health.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
